Scinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston

2 years ago

Major shareholder announcement – BlackRock, Inc.

2 years ago

Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19 

2 years ago

Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference

2 years ago

Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer

2 years ago

EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023

2 years ago

Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer

2 years ago

Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse

2 years ago

APRINOIA Therapeutics Announces Strategic Investment From The Alzheimer’s Drug Discovery Foundation (ADDF)

2 years ago

Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors

2 years ago

Show more Posts
Show previous Posts